Bacterial Genetics and the Limits of Chemical Therapy: A 1981 Retrospective?

Bacterial Genetics and the Limits of Chemical Therapy: A 1981 Retrospective was a comprehensive assessment published in the Journal of Bacteriological History by a consortium of researchers at the Institute for the History of Bacteriology in Berlin, written under the direction of Richard Reinhardt. The paper examined the trajectory of azo drug resistance and argued, from first principles of bacterial genetics, that no sustainable chemical basis for systemic infection control had ever existed in this civilization, and that the institutional development of asepsis maximalism represented not a failure of chemistry but an inevitable scientific recognition of bacterial adaptation.

The retrospective emerged at a moment of institutional consolidation. By 1981, the Halloway-Umezaki serum therapy was in wide clinical use across wealthy nations, having displaced azo drugs as the preferred treatment for systemic infections since its widespread licensing in 1979. Yet persistent professional disagreement persisted over whether this transition represented genuine progress or merely a pragmatic accommodation to irreducible limits. The Berlin consortium's paper attempted to reframe the question: the authors argued that the question itself was wrongly posed. Chemical therapy had never been viable as a systemic answer to infection because bacteria themselves were not static targets.

The paper built on work by Joshua Lederberg, the American microbiologist who had established in the 1950s that bacterial genetic variation was continuous, heritable, and subject to selection pressure in any population exposed to a selective agent. Where an antimicrobial chemical killed the majority of bacteria in an infection but not all, survivors—those carrying genetic variation that conferred resistance—would reproduce preferentially in the absence of their competitors. Within a human host over days or weeks, this produced a population shifted toward resistance. Administered repeatedly to the same patient or across a population, chemical therapy inevitably selected for resistance far faster than new compounds could be synthesized.

The retrospective provided statistics drawn from the Bayer archives and from Geneva Sanitary Bureau records spanning the 1940s through 1970s. Resistance to the primary azo drugs had emerged clinically within three to seven years of widespread adoption in most populations, and rates of resistance had continued climbing throughout the postwar period despite the introduction of successively modified azo compounds. The authors tabulated data from 47 nations showing that by 1975, azo drugs were effective against fewer than 40 percent of common nosocomial bacterial infections in most major hospitals, and in some urban centers effectiveness had fallen below 20 percent.

The serum therapy alternative, the paper argued, functioned differently in evolutionary terms. Rather than imposing a selection pressure that favored resistant variants, antibody-based treatment relied on recognition of conserved bacterial antigens—markers that bacteria could not rapidly alter without sacrificing essential functions. Serum therapy thus escaped the trap that had always constrained chemical approaches: it did not create conditions favoring the evolution of resistance.

The paper also examined the institutional response. From the Bacillary Congress of 1952 onward, public health authorities had begun formulating policy as if systemic chemical control of infection would always be limited and temporary. This was not, the authors contended, conservative thinking or institutional pessimism. It was empirical bacteriology applied to institutional design. The fortress hospitals, the air filtration, the segregation protocols, the disposable everything—these had emerged not as a grudging stopgap while chemistry caught up, but as a rational response to a permanent constraint.

One scholarly disagreement persisted over the retrospective's treatment of the 1943-1945 period. Some military medical historians argued that the massive wartime casualties from sepsis and gangrene, far exceeding those in the previous conflict, resulted from inadequate supply of azo drugs and poor distribution rather than from the drugs' inherent limits. The retrospective's authors countered that supply figures from the Bayer AG Manufacturing Archives showed azo drug production in 1944 and 1945 exceeded all previous years, and that when analyzed by infection type and treatment duration, resistance patterns were already evident in the statistical record.

The paper found its widest circulation not in chemical or pharmaceutical literature but in institutional history and public health policy circles. By the early 1980s, it provided empirical grounding for what had become obvious in practice: that the civilization had not failed to find a cure because cure was insufficiently sought, but because cure was not available to find. The only question remaining was how to live well within that constraint. The retrospective did not resolve how, but it clarified why—and clarity itself was the contribution that mattered.

The emergence of resistance does not prove the inadequacy of the drug. It proves the adequacy of natural selection. When we administer a chemical that kills 99 percent of bacteria, we do not eliminate infection; we select for the 1 percent. Over time, this becomes the population. The cycle repeats. There is no chemistry that escapes this. Only immunity, which requires no killing and no selection, offers escape.

— Introduction, ''Bacterial Genetics and the Limits of Chemical Therapy: A 1981 Retrospective''